In vitro measurement and screening of monoclonal antibody affinity using fluorescence photobleaching.

J Immunol Methods

Department of Chemical Engineering, Carnegie Mellon University, Pittsburgh, PA 15213-3890.

Published: October 1992

Antibody screening is a routine in vitro assay in monoclonal antibody development and production. We have recently adapted the fluorescence photobleaching method to quantify antibody mass transport and binding parameters in bulk solution (Kaufman and Jain, 1990, 1991). The present study uses this in vitro method to screen a series of monoclonal antibodies (IgG) developed against the rabbit VX2 carcinoma tumor line. These experiments indicate that the three antibodies recognize distinct epitopes on the tumor, with equilibrium binding constants of 1.3 +/- 0.5, 5.1 +/- 3.6 and 2.0 +/- 1.1 x 10(7) M-1 for the antibodies RVC-184, RVC-626 and RVC-779, respectively. The antibody diffusion coefficient revealed no dependent upon protein concentration or antigen bead volume fraction within the ranges investigated. It was demonstrated experimentally that the interactions conformed to a reaction limited binding model of fluorescence recovery, that the system was at equilibrium, and that non-specific binding due to the fluorescein probe was not significant. Once the non-reactive fraction of antibody is determined, this photobleaching technique does not require perturbation or physical separation of the unbound species. As such, it has many potential applications including in vivo investigation of binding parameters.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0022-1759(92)90265-uDOI Listing

Publication Analysis

Top Keywords

monoclonal antibody
8
fluorescence photobleaching
8
binding parameters
8
+/- +/-
8
antibody
6
binding
5
vitro measurement
4
measurement screening
4
screening monoclonal
4
antibody affinity
4

Similar Publications

Neonates are susceptible to respiratory viral infections, with outbreaks reported in areas with a high population of neonates, such as postpartum care centers and neonatal wards. While specific antiviral drugs are currently available for influenza, symptomatic supportive treatment remains the primary approach for respiratory syncytial virus (RSV), making prevention particularly important. The article closely follows the "Expert recommendations for the prevention of common respiratory viral infections in neonates" and provides an in-depth interpretation of recent breakthroughs in RSV prevention.

View Article and Find Full Text PDF

Antibodies targeting either the calcitonin gene-related peptide (CGRP), such as galcanezumab, fremanezumab, and eptinezumab, or the receptor (erenumab) have been approved for the prevention of episodic and chronic migraine. Although widely used and generally effective, a proportion of patients discontinue treatment due to lack of efficacy. In both randomized controlled trials and observational studies, all anti-CGRP monoclonal antibodies (mAbs) have consistently demonstrated comparable efficacy and tolerability, suggesting a pharmacological class effect.

View Article and Find Full Text PDF

Background: A recent prospective phase II study (ECOG-ACRIN E2211) demonstrated that MGMT deficiency was associated with a significant response to capecitabine and temozolomide (CAPTEM) in pancreatic neuroendocrine neoplasms (NENs); however, routine MGMT analysis in NENs was not recommended. Our study sought to demonstrate whether loss of MGMT protein expression is associated with improved overall survival (OS) in patients receiving CAPTEM for NENs from various tumor sites.

Materials And Methods: Paraffin-embedded tumor samples were evaluated by immunohistochemistry (IHC) using an MGMT monoclonal antibody.

View Article and Find Full Text PDF

The epitope of the antibody used in the REAADS VWF activity assay is quaternary.

Thromb J

January 2025

Division of Hematology, Departments of Internal Medicine and Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.

The REAADS VWF activity assay is often assumed to be specific for the A1 domain, the portion of VWF that binds platelet GPIbα. We tested this assay on the A1A2A3 region of VWF with each domain expressed independently of one another and together in combination as a tri-domain. The monoclonal antibody used in this assay is found to be insensitive to the single A domains and does not recognize free A1 domains as it is often assumed.

View Article and Find Full Text PDF

Background: Migraine progression, particularly from episodic to chronic migraine (CM), increases disease burden and healthcare costs. Understanding the new concept of "Medication Underuse Headache" should encourage the health care provider to consider early intervention with calcitonin gene-related peptide (CGRP) monoclonal antibodies. Galcanezumab given early in the course of the disease, may prevent migraine chronification and have a robust response, moreso than when initiated in later stages of migraine.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!